

**KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
KUMASI, COLLEGE OF HEALTH SCIENCES
DEPARTMENT OF CLINICAL AND SOCIAL PHARMACY**

**ANTIBACTERIAL USE AND RESISTANCE PATTERN AT THE ACCIDENT AND
EMERGENCY DEPARTMENT OF KOMFO ANOKYE TEACHING HOSPITAL**

By

DANIEL APPIAH

MARCH, 2015

**ANTIBACTERIAL USE AND RESISTANCE PATTERN AT THE
ACCIDENT AND EMERGENCY DEPARTMENT OF KOMFO ANOKYE
TEACHING HOSPITAL**

BY

**DANIEL APPIAH
B. PHARM (HONS)**

**A THESIS SUBMITTED TO THE DEPARTMENT OF CLINICAL AND
SOCIAL PHARMACY, FACULTY OF PHARMACY AND
PHARMACEUTICAL SCIENCES, KWAME NKRUMAH UNIVERSITY
OF SCIENCE AND TECHNOLOGY, IN PARTIAL FULFILLMENT OF
THE REQUIREMENTS FOR THE AWARD OF MASTER OF SCIENCE IN
CLINICAL PHARMACY**

MARCH, 2015

DECLARATION

I hereby declare that this submission is my work towards an award of degree of Master of Science in Clinical Pharmacy and that, to the best of my knowledge, it contains no material previously published by another person, nor material who has been accepted for the award of any other degree of the University, except where due acknowledgment has been made in the text.

Daniel Appiah (PG5976711)

.....

.....

Student Name & ID

Signature

Date

Certified by:

Dr. Kwame Ohene Buabeng

.....

.....

Head of Department &Project Supervisor

Signature

Date

DEDICATION

This work is dedicated to the almighty God and to my family for their immerse support throughout this course.

ACKNOWLEDGEMENT

My greatest gratitude goes to the almighty God for giving me the strength to go through my MSc. programme. I wish to thank the Head of Department of Emergency medicine-Komfo Anokye Teaching Hospital (KATH), Dr. George Oduro and Head of Clinical Microbiology-KATH, Prof. E. Frimpong for giving me the permission to carry out this research. Not forgetting my immediate boss and Head of Pharmacy at the Emergency Medicine directorate, Mr. Michael Assenso for his support through the programme. Special thanks to all my colleagues at work especially Pharm. Lesley Boatey, Pharm. Afia Nkansah-Sarkodie, Pharm. Akua Afriyie Appiah and Pharm. Grace Sobotie for their help. I also thank my parents for the support and love they have shown towards my education and career to date. I further wish to say a big thank you to my supervisors, Dr. Kwame Ohene Buabeng and Dr. Alex Owusu-Ofori for their support and guidance, without them this thesis would have been nearly impossible. Finally, I cannot forget the contribution of all my lecturers at the Department of Clinical and Social Pharmacy, KNUST especially Mr. Joseph Attakorah in helping me through this programme.

ABSTRACT

Background and Objectives: Antimicrobial resistance is a major problem all over the world due to indiscriminate and inappropriate use of antimicrobials both in healthcare facilities and in communities. The Accident and Emergency Department (AED) serves as a major area where antimicrobial therapy is initiated for severe infections but data on use of antimicrobial agents in these setting are lacking in Africa. This study aim was to determine the appropriateness of antibacterial use as well as antibacterial resistance patterns of commonly isolated bacteria at AED of Komfo Anokye Teaching Hospital (KATH).

Methodology: This was prospective observational study undertaken from 1st March to 30th April, 2014. Two hundred and eighty-two patients at the AED wards were selected by systematic random sampling from 1119 patients exposed to antibacterials out of total 1942 admitted within the study period. These patients were then followed on daily for data on antibacterial use. From 85 of the admitted patients, 90 specimens were taken for culture and sensitivity testing at the Medical Microbiology laboratory of KATH. The specimens included blood (n=37), others such as ascitic fluid, pleural fluid and knee joint aspirate (n=28), urine (n=15), cerebrospinal fluid (n=5) and wound swab (n=5). Appropriateness of antibacterial use was assessed based on recommendations in the Standard Treatment Guidelines-2010 of Ghana and other international standard guidelines accepted globally and adapted by clinicians at KATH.

Results: In all 1119 out of 1942 patients encountered within the study period were prescribed antibacterials, representing a prevalence of 57.6%. Of the 282 sampled, 61.7% (n=174) were on curative antibacterial therapy and 38.3% (n=108) were on prophylactic therapy. Cefuroxime was

the most prescribed antibacterial agent (DDD/100days: parenteral 36.119; oral 75.850) and Doxycycline (DDD/100days: oral 16.689) was the least prescribed. Seventy percent (n=196) of antibacterial prescriptions were considered appropriate based on recommendations in the approved standard guidelines. For those patients on curative antibacterial therapy who were followed (n=123), 15.4% (n=19) died, 56.1% (n=69) had improvement in their clinical status and general well-being, and 28.5% (n=35) had their symptoms worsening.

Twenty-six percent (n=23) of the 90 specimens recorded bacterial growth. The most common isolates were *E. coli* (n=10), Coagulase Negative *Staphylococcus* (n=6, possibly contaminants of blood and ascitic fluid specimens), *Klebsiella spp* (n=4), *Pseudomonas spp* (n=2) and MRSA (n=1). Over 70% of the *E. coli* isolates tested were resistant to ceftriaxone, cefuroxime, ciprofloxacin and cotrimoxazole. The *Klebsiella* isolates were resistant to cefuroxime, cotrimoxazole and ceftriaxone.

Conclusion: The rate of antibacterial prescribing at AED was high, with a third of the prescriptions considered inappropriate. *Klebsiella* and *E coli* isolates from patient samples sent to the laboratory were resistant to broad spectrum antibacterial agents like ceftriaxone and cefuroxime. Antimicrobial agents should therefore be used more responsibly, guided by culture and sensitivity data for definitive therapy. This would minimize morbidity and mortality from infectious diseases as well as the risk of emergence and spread of antimicrobial resistance in hospitals.

TABLE OF CONTENTS

Contents	Page
DECLARATION	ii
DEDICATION	iii
ACKNOWLEDGEMENT	iv
ABSTRACT.....	v
TABLE OF CONTENTS.....	vii
LIST OF TABLES	ix
LIST OF FIGURES	x
LIST OF ABBREVIATIONS	xi
CHAPTER ONE	1
1.1 INTRODUCTION	1
1.2 Rational of the study	3
1.3 Main Aim	3
1.3.1 Specific Objectives	3
CHAPTER TWO	5
2.1 LITERATURE REVIEW	5
2.1.1 History of antibacterials	5
2.1.2 General use of antibacterials and resistance.....	6
2.1.3 Use of antibacterial agents in emergency departments	7
2.1.4 Use of Culture and Sensitivity testing in Emergency Departments	8
2.1.5 Principles of antibacterial prescribing.....	9
2.1.6 Methods of evaluating antibacterial use.....	10
2.1.7 Antibacterial resistance	12
2.1.7 Combating Resistance.....	13
CHAPTER THREE	15
3.1 METHODOLOGY	15
3.1.1 Study design.....	15
3.1.2 Study settings	15
3.1.3 Target population	17

3.1.4	Inclusion criteria	17
3.1.5	Exclusion criteria	18
a)	Assessing prevalence of antibacterial use	18
b)	Assessing appropriate antibacterial use and patient outcomes.....	18
c)	Determining antibacterial resistance	22
3.1.6	Data Analysis	24
3.1.7	Ethical Consideration	25
CHAPTER FOUR.....		26
4.1	RESULTS	26
a)	Prevalence of antibacterial use.....	26
b)	Appropriateness of antibacterial use and patient outcomes	26
c)	Resistance patterns of isolated bacteria.....	35
CHAPTER FIVE		38
5.1	DISCUSSION	38
5.2	LIMITATIONS OF THE STUDY	42
CHAPTER SIX.....		43
6.1	CONCLUSION	43
6.2	RECOMMENDATIONS	43
REFERENCES		44
APPENDICES		53
APPENDIX 1: DATA COLLECTION FORM FOR WARD DATA		53
APPENDIX 2: DATA COLLECTION FORM FOR MICROBIOLOGY LAB.....		55
APPENDIX 3: COPY OF ETHICAL APPROVAL LETTER.....		56

LIST OF TABLES

Table 1: Prophylactic and curative use of antibacterial agents in the wards.....	27
Table 2: Affected body systems requiring antibacterial agents	27
Table 3: Comorbidities of study participants.....	28
Table 4: Pattern of prescribed antibacterials	29
Table 5: Patient clinical status following curative antibacterial therapy	34
Table 6: Frequency of bacterial isolates from the different specimen types.....	35
Table 7: Isolated organisms and their resistance to the various antibacterial agents	37

LIST OF FIGURES

Figure 1: Flowchart for assessing the quality of antimicrobial drug prescription	11
Figure 2: Study flow chart on patients included in the study and monitored for antibacterial use and outcomes	21
Figure 3: Study flow chart on AED patients with biological samples assessed for resistance.....	23
Figure 4: Number of antibacterial agents patients were exposed to.	30
Figure 5: Choice of selected antibacterial agent(s) in line with recommendation in approved guidelines	31
Figure 6: Appropriate antibacterial therapy as indicated by the standard guidelines	32
Figure 7: Request for culture and sensitivity testing	33

LIST OF ABBREVIATIONS

AED	Accident and Emergency Department
ATC	Anatomical, Therapeutic and Chemical
CDC	Centers for Disease Control and Prevention
CDU	Clinical Decision Unit
CHRPE	Committee on Human Research, Publication and Ethics
CNS	Coagulase Negative <i>Staphylococcus</i>
C/S	Culture and Sensitivity testing
CSF	Cerebrospinal fluid
DDD	Defined Daily Dose
HIV	Human Immunodeficiency virus
ICU	Intensive Care Unit
KATH	Komfo Anokye Teaching Hospital
KBTH	Korle Bu Anokye Teaching
KNUST	Kwame Nkrumah University of Science and Technology
MRSA	Methicillin Resistance <i>Staphylococcus aureus</i>
SATS	South African Triage Scale
SME	Surgical and Medical Emergency
SPSS	Statistical Package for Social Sciences
STG	Ghana Standard Treatment Guidelines-2010
TEWS	Triage Early Warning Score
UTIs	Urinary Tract Infections
WHO	World Health Organization

CHAPTER ONE

1.1 INTRODUCTION

Inappropriate use of antibacterial agents is a global health concern because of the increasing rate of bacteria resistance to antibacterial agents and poor treatment outcomes from antimicrobial therapy (1). In 2001, the World Health Organization (WHO) announced a global strategy involving all stakeholders to combat the emergence and spread of antimicrobial resistance (2). Also on 7th April, 2011 during the World Health Day, WHO further reiterated a policy package to combat the spread of antimicrobial resistance with a call “to action today to protect our antibiotics tomorrow” (3). In 2013, the Centers for Disease Control and Prevention (CDC) in its maiden report on antimicrobial resistance threats in the United States reiterated the global threat of antibacterial resistance (4).

In Ghana, there is paucity of data on the appropriateness of use of antibacterial agents in the clinical setting although resistance of bacteria to some of these agents is high. Newman *et al* (2006) in their study established that commonly isolated bacteria in Ghana including *Staphylococcus aureus* and *Salmonella typhi* were multidrug resistant (5,6). A study also done in Korle bu Teaching hospital identified nasal colonization of drug resistant strains in children under five (7). Another study by Sanaa *et al* in 2013 identified the presence of resistant strains of *Staphylococcus aureus* isolates to most of the commonly used antibacterial agents in three hospitals in Kumasi (8).

The hospital and societal cost of antibacterial misuse is high. In a study in Chicago involving a sample of 1391, 13.5 % had a resistant bacteria with the societal cost estimated to be \$13.35 million in 2008 dollars (9).

There is a decline in development of new antibacterial agents by pharmaceutical companies (10) as result of poor return on their investments and failure of discovery of new antibacterial agents based on traditional models of discovery among other reasons (11,12). This places much responsibility on all stakeholders to protect the antibacterial agents currently in use.

In Emergency department of hospitals, because of the urgent needs of most patients' conditions, the interaction between patients and physicians is at times sporadic in nature. This results in most antibacterial prescriptions being empirical or prophylactic. From a study in an emergency department of a tertiary hospital in Taiwan, inadequate empirical antibacterial therapy has been shown to be associated with higher mortality rates (13). A study by Kang *et al*, also showed the increased mortality among bacteraemic patients is associated with inappropriate first antimicrobial therapy (14).

The strategic position of emergency departments makes the prompt and appropriate antibacterial therapy a major contributory factor in good patients' outcomes as antibacterial therapy often start at the department for most patients.

There are various means of determining outcomes of antibacterial therapy in an infection. This includes clinical cure (where resolution of signs and symptoms are used)(15,16), microbiological cure (which involves microbial eradication after treatment), economic (which includes hospital stay days) and ecological outcomes (where resistance rates of commonly isolated organism are determined)(17). However, clinical studies on antibacterial efficacy mostly use two main parameters for the study; clinical improvement/clinical cure and microbiological cure (18).

1.2 Rational of the study

Inadequate data on antibacterial use at Accident and Emergency Department (AED) of the Komfo Anokye Teaching Hospital (KATH) poses a great challenge to rational use of antibacterials in the department and KATH at large. KATH does not currently have an antibacterial stewardship program which includes antibacterial prescribing guidelines. Thus the extent of use of antibacterials whether rationally or irrationally is unknown. This study will provide evidence on the appropriateness of antibacterial use at AED and also highlight the resistance pattern of commonly isolated bacteria during the study period. This study will serve as a baseline study and a guide to the implementation of KATH antibacterial stewardship programme. It will also inform all stakeholders and policy makers in their effort towards promoting rational antibacterial use and support incorporating appropriate antibacterial use in our antimicrobial surveillance system in KATH.

1.3 Main Aim

The aim of this study is to describe antibacterial resistance patterns of commonly isolated bacteria and the appropriate use of antibacterials at the AED of KATH.

1.3.1 Specific Objectives

1. To assess the prevalence of use of antibacterials at the AED of KATH.
2. To assess the antibacterial prescription pattern at AED and calculate the DDD/100 bed-days of commonly used antibacterial agents.
3. To assess the quality (or appropriateness) of antibacterial prescriptions at the AED.
4. Ascertain the extent of microbiological culture and sensitivity request at the AED.
5. Determine the sensitivity and resistance pattern of commonly isolated bacteria from specimen collected at the AED during the study period.

6. Assess the outcome (or clinical status) of patients following curative antibacterial therapy.

CHAPTER TWO

2.1 LITERATURE REVIEW

2.1.1 History of antibacterials

The use of natural product mixtures to treat infections dates from ancient times (19) and there is evidence of tetracycline in human skeleton dating back to AD 350-550 (20). The gradual acceptance of the germ theory of disease which suggested that infectious disease was caused by microbes, led to a search for a means to kill these implicated microbes. In 1907, Paul Ehrlich in his search for a “magic bullet” to cure infectious diseases led to the discovery of Salvarsan, the first chemical compound used in treating syphilis. In 1928, Sir Alexander Fleming observed that *Penicillin notatum* had contaminated bacterial culture plates of *Staphylococcus aureus* and there was growth inhibition of the *S. aureus* at the point of contact. This led the discovery of penicillin. However it was not until 1940, that a purification process was developed to produce sufficient quantities for clinical trials. In 1942, mass production and distribution of penicillin began (21). This marked the beginning of the “antibiotic era”: The term antibiotic was first used by Selman Waksman in 1941 (22).

Antibiotics, since the discovery of penicillin, have played an important role in health. However the use of antibiotics is associated with its own inherent problems. Based on the theory of evolution, it is known that microbes develop factors that enable them to resist the action of antibiotics especially on repeated exposure (23).

2.1.2 General use of antibacterials and resistance

Various studies have showed that increased and inappropriate use of antibacterials has been a major factor to the development of microbial resistance in hospitals and the community (24). In Europe, countries with high antibacterial agents consumption have high resistance rates (25). This shows the positive correlation between antibacterial use and resistance. In Ghana, antibacterial agents are one of the most prescribed agents (26). The appropriate use of antibacterials has therefore become an important factor in combating antibacterial resistance in the hospital setting. This necessitates everybody especially health professionals to ensure that antibacterial agents are used appropriately so as to minimize resistance.

There is a growing problem of antibacterial resistance in Africa and other developing countries (27–29). In Ghana, many clinically important microbes have shown resistance to most commonly used antibacterial agents to which they were initially susceptible (6,30). A study by Nys *et al* (2004) in eight developing countries including Ghana showed resistant strains of *E. coli* to cefazolin, gentamicin and ciprofloxacin (31). Quinolone resistant *E. coli* has also been found to be common in Accra, Ghana (32).

A study by Obeng-Nkrumah *et al* (2013) in Korle-bu Teaching Hospital (KBTH) which is a major referral center in Ghana with similar characteristics as KATH, found a high level of Extended-spectrum beta-lactamase (ESBL)–producing Enterobacteriaceae among neonates and adults over 65 years indicating high selective pressure associated with massive antibacterial agent use (33). Another study by Feglo *et al* at KATH also found ESBL producing strains of *E. coli* (34).

A sustained reduction of antibacterial use led to a drop of methicillin resistant *Staphylococcus aureus* (MRSA) and *Clostridium difficile* infections in a tertiary hospital in the United States (35). This demonstrates the effect of reduced antibacterial use on resistance pattern on bacteria. A study by Bronzwaer *et al* on the relationship between antibacterial use and bacteria resistance patterns in Europe implicated the increased use of beta-lactam antibiotics and macrolides as being associated with increased bacteria resistance (25). A study in Europe also demonstrated the positive association between inappropriate antimicrobial use and resistance (36).

2.1.3 Use of antibacterial agents in emergency departments

There is scarcity of reports on antibacterial use in emergency settings in Africa. In Ghana, not much has been officially reported as the AED in KATH is a recent development. However, available reports on antibacterial use in emergency and acute care settings in other jurisdictions demonstrate a high level of inappropriate and unnecessary use of antibacterial agents. A study found 77% of antibacterial prescription changed within the first 24 hours and by 72 hours most patients had received at least 3 antibacterial agents(37). A study by Gonzales *et al* demonstrated high prevalence of indiscriminate antibacterial use in acute respiratory infections in emergency setting (38). Stone *et al* (2000) also found antibiotics commonly prescribed for emergency patients with common cold and upper respiratory tract infections (24.2%), and bronchitis (42.2%) even though they were unwarranted and ineffective (39). Though there have been reported decrease in antibacterial usage for acute respiratory tract infections in the United States from 1995 to 2000, antibacterials still accounts for half of the prescription written for these subsets of patients (40). Despite campaign effort by the Centers for Disease Control and Prevention (CDC) to combat unnecessary antibacterial use, a study by Xu *et al* (2013) found an

unnecessary high use of antibacterial agents in uncomplicated upper respiratory tract infections which did not require these agents (41). In another study, emergency physicians were likely to prescribe antibiotics in acute diarrhea because they assumed patient expected them to even though they were correct in 33% of their prescriptions (42).

Another challenging factor is the association of antibacterial prescription and patient satisfaction. In a study involving patients with acute respiratory infection in an emergency setting, some patient derived satisfaction on receiving an antibacterial prescription (43) while in others satisfaction was not related to receiving antibacterial agents (44). In another study assessing the appropriateness of antibacterial prescription in the emergency department found only 53% of antibacterial prescription appropriate and 34% following guidelines (45). A Spanish study also found 43% incorrect antibacterial prescriptions in an emergency department (46).

2.1.4 Use of Culture and Sensitivity testing in Emergency Departments

In emergency situations, it is prudent to initiate antibacterial in suspected bacterial infectious conditions before culture and sensitivity testing results of samples are ready. Though it is a standard practice to request for culture and sensitivity testing in most infectious conditions, its utility in the emergency department for pneumonia has been questioned and are said to be rarely useful in some studies in developed countries(47–49). In some of these studies with patients with bacteremic pneumonia, it was observed that blood cultures infrequently change therapy with patients with pneumonia(50–52). As a result of this, Shapiro *et al* developed a clinical decision rule to optimize the use of blood cultures in the emergency department (53). This decision rule utilizes a set of major criteria and minor criteria to classify patients as high or low

risk. It is only in the high risk patients that blood cultures mostly yield positive results. However, it must be noted that positive culture results is always the key to definitive antibacterial therapy.

2.1.5 Principles of antibacterial prescribing

Various principles govern the use of antibacterials in the clinical setting. According to the British National formulary, the patient and the likely organism believed to be causing the infection are the factors that must be considered in selecting an antibacterial agent. The pharmacological/toxicological properties as well as microbiological efficacy of the antibacterial agent must be taken into consideration whether it is for prophylaxis, empirical, or definitive therapy (16,54).

Prophylactic antibacterial therapy is when one or more antibacterial agents are given to prevent an infection. Empirical antibacterial therapy is when one or more antibacterial agents are given in a situation where the microbe is unknown at the start of therapy but guided by the local sensitivity data of possible organisms. Definitive antibacterial therapy is when one or more antibacterial agents is directed against an identified microbe based on positive microbiological culture results (16). For this study, Empirical and definitive antibacterial therapy are termed Curative antibacterial therapy.

Appropriate antimicrobial prescribing as defined by CDC is “prescribing antimicrobials only when they are likely to be beneficial to the patient, selecting agents that will target the likely pathogens, and using these agents at the correct dose and for the proper duration” (55).

2.1.6 Methods of evaluating antibacterial use

There are various methods in determining antibacterial use in hospitals. However, the pioneering work of Kunin *et al* (1973) serves as the basis for assessing the quality of antimicrobial prescribing in health care settings (56). A flow chart by Gyssens *et al* (1992) developed based on the original work of Kunin *et al* (56) as shown in Figure 1 below, has been used to assess all aspects of antimicrobial prescribing (57,58). Using the flow chart, an antibacterial prescription can be assessed using any of the descending roman numerals (that is from VI through O) or a combination in line with recommendations in approved guidelines.

From the flow chart, the decision to use an antibacterial agent, the indication, choice of medication, toxicity, cost, dose, dosage frequency, duration, route and time of administration in line with clinical condition as stated in approved standard treatment guidelines provides a means of assessing the appropriateness antibacterial therapy (58). A prospective clinical audit carried out in a university hospital in France using the Gyssens *et al* flow chart for evaluating antibacterial prescription appropriateness found 64% of antibacterial prescriptions inappropriate or unnecessary (59)

Point or period prevalence studies, where the proportion of patients on antibacterial agents at a specific time or period is determined, have also been used to assess the prevalence of antibacterial use at a point in time or over a period (60–64).




Figure 1: Flowchart for assessing the quality of antimicrobial drug prescription [by Gyssens *et al* (57,58)]

AB= Antimicrobial agent

Another method such as the Anatomical, Therapeutic and Chemical (ATC) Classification / Defined Daily Dose (DDD) methodology developed and maintained by the WHO Collaborating Centre for Drug Statistics Methodology can also be used to compare the antibacterial agents consumption between countries, hospitals or even departments within the same hospital (65,66). This method is used to determine the DDD per 100-bed days for antibacterials used within in a health care facility during a period. For example if the calculated DDD per 100 bed-days for cefuroxime use in a health care facility is 50 DDD per 100 bed-days, this implies that 50% of the patients may receive a DDD of cefuroxime every day. In Ghana, there is lack of data on antibacterial use burden based on the ATC/DDD methodology.

These methods of antibacterial use evaluation help in antibacterial stewardship with the aim of minimizing antibacterial resistance and improving treatment outcomes.

2.1.7 Antibacterial resistance

Antibacterial resistance is said to occur when a bacteria is able to withstand the action of an antibacterial agent to which it was previously susceptible (67). Antibacterial resistance can occur across all or some strains of the supposed bacteria. A bacterium can have innate or acquired resistance. Innate resistance is based on the unique genetic code of the organism giving it the ability to pass its genes to its progeny by means of reproduction (also called vertical gene transfer). Example is resistance of *E. coli* to vancomycin. Acquired resistance occurs through chromosomal mutation or horizontal gene transfer (HGT). HGT is the transfer of genes from one bacterium to another other than traditional reproduction (or vertical transfer). HGT occurs by means of mobile genetic factors such plasmids, integrons, transposons or bacteriophages through

conjugation, induction and transformation. Once the bacteria have these resistance genes in their genetic make-up, they are able to protect themselves from several antibacterial agents through a variety of resistance mechanisms (68). These resistance mechanisms include destruction of the antibacterial agent by the bacterium (e.g. beta-lactamases), modification of the antibacterial target site, bypassing the action of the antibacterial through production of alternative pathways, and prevention of the drug from reaching its target site through efflux mechanisms or decreasing its permeability into the bacterium(69,70).

Though resistance of bacteria can occur naturally, the use of antibacterial agents have been observed to hasten the process of acquired resistance by bacteria. Indiscriminate and excessive use in the clinical setting and use of antibacterials for agricultural purposes are all contributory factors to the development of resistance (71). Poor quality antibacterials have also been noted as contributing to resistance development especially in developing countries. As a result, treatment failures from poor quality antibacterials necessitate the use of reserved second line antibacterials (72). Other physical factors contributing to the spread of resistant strains include movement of patients within and among healthcare institutions, lack or inadequacy of infection control measures, and general movement of goods and people (73).

2.1.7 Combating Resistance

CDC in its 2013 annual report identified four main ways of fighting antibacterial resistance. These are infection prevention, tracking of resistance patterns, antibacterial stewardship and development of new antibacterial diagnostic testing (4). These measures are aimed at the health facility, prescribing and dispensing angle of combating antibacterial resistance.

Antibacterial stewardship are various measures implemented to promote appropriate use of antibacterials (74). Various countries have developed and implemented antibacterial stewardship program and evidence from various studies confirms the benefits of these stewardship program (75–79). Antibacterial stewardship ensures prudent use of antibacterials in health care settings and minimizes antibacterial resistance. Antibacterial ward rounds (80) of infectious disease specialist and antibacterial restriction policies(81) are all components of antibacterial stewardship program applied in various settings.

CHAPTER THREE

3.1 METHODOLOGY

3.1.1 Study design

This was a prospectively observational study with three areas of focus. These were;

- a) Prevalence of antibacterial use, where the proportion of patients prescribed antibacterial agents during the study was determined.
- b) Appropriateness of antibacterial use, pattern of use and patient outcomes, where data was collected prospectively from a randomly selected sample in the wards.
- c) Resistance pattern of bacteria isolates to antibacterial agents, where data from all AED patients with culture and sensitivity request was assessed from the Medical Microbiology lab.

3.1.2 Study settings

KATH is a 1200 bed capacity teaching hospital located in Kumasi, the second largest city in Ghana. The study settings were the Accident and Emergency Department (AED) of KATH and the KATH medical microbiology lab.

3.1.2.1 Accident and Emergency Department (AED)

The AED is responsible for the provision of emergency medical and surgical services to mostly adult clients. The AED has three main emergency wards namely Red, Orange and Yellow wards where emergency services are provided. Patients are assigned to Red, Orange and Yellow wards

based on the urgency of emergency care they require. The urgency of care is decided using the validated South African Triage Scale (SATS) which relates a score of a patient to the assigned ward (82–84). The SATS consists of three age-specific tools. The age-specific tools are the Adult tool, Child tool and Infant tool. The Adult tool is for patients aged 12 years and above or height above 150cm. The Child tool is for patients aged 3 to 12 years or height from 96 to 150cm. The Infant tool is for patients under 3 years or height 95cm and below.. The content of each tool consists of a range of parameters with scores assigned to generate the Triage Early Warning Score (TEWS). A TEWS of above 7 admits the patient to Red which indicates the patient needs immediate treatment. A TEWS of 5-6 admits the patient to Orange indicating treatment should commence within 10 minutes. A TEWS of 3-4 admits the patient to Yellow indicating the patient needs treatment within 60 minutes. A TEWS of 0-2 is assigned the code colour Green which indicates the patient has non-emergency condition and therefore should be referred to a primary care facility. A patient brought in dead is assigned code Blue.

The parameters measured to generate the TEWS include mobility, heart rate, temperature, blood pressure, respiratory rate, trauma history and consciousness level. The TEWS also allows for a senior health professional discretion in assigning a patient to a ward (85). A patient after being triaged to a ward is assigned a folder. The attending physician documents all relevant data after assessing the health condition of the patient and may prescribe medications and/ or recommend the necessary investigation such as culture and sensitivity to be done in line with the clinical presentation of the suspected condition.

The AED Pharmacy is also an integral part of Accident and Emergency Department. Prescriptions in folders of patients on admission or detained at the AED are sent to the pharmacy and assessed to rule out any medication related problems, after which the prescribed

medications are supplied to nurses to be taken back to the respective ward. In the pharmacy, patient relevant data including dispensed medication are entered manually into the pharmacy records and also in the patients' folder before the medications are supplied. Patient records maintained in the pharmacy includes patients name, age, sex, ward, medications supplied and dates the medicines were supplied.

3.1.2.2 KATH Medical microbiology laboratory

In the Medical microbiology laboratory, specimen for culture and sensitivity testing are received on a request form signed by the physician attending to the patient from which the specimen was taken. Details on the request form include the patients name, age, sex, ward, specimen type, diagnosis/clinical summary and date of request. The specimen is given a unique code after which all data on the request form entered in the microbiology records. The specimen are then processed and when the results become available, the particular patient record is updated in the microbiology records with the help of the unique code.

3.1.3 Target population

The population targeted in this study was all patients admitted at Red, Yellow and Orange wards at AED, KATH.

3.1.4 Inclusion criteria

Patients admitted to the AED wards

3.1.5 Exclusion criteria

Patients admitted to the Critical decision unit ward (CDU), Intensive Care Unit ward (ICU), Burns Intensive Care Unit ward, Theatre recovery ward, Special awards as well as patients who were unconscious.

a) Assessing prevalence of antibacterial use

For the prevalence of antibacterial use, data on all admitted patients gathered within the study period was used.

Data collection on prevalence of antibacterial use

Data on all admitted patients were entered into a specially designed data sheet (Microsoft Excel workbook) as their folders came to the pharmacy for medication. This enabled the assessment of patients exposed to antibacterial therapy, out of the total number admitted to the AED wards within the study period.

b) Assessing appropriate antibacterial use and patient outcomes

For the appropriate antibacterial use, pattern of use and patients' outcomes, data was gathered from the sample of patients on antibacterial therapy at the AED wards.

Sample size for study participants

Since this study had three focus areas, an appropriate sample size was estimated to guide the selection of study participants for data on appropriateness of antibacterial therapy, pattern of use and patients' outcomes.

Thus assuming 50% of patients in the AED wards were exposed to antibacterial agents, using a delta (or margin of error) of 0.055 and within 95% confidence limit, a population size of approximately 2200 patients for two months would require at least 278 participants. However, a total of 282 participants were selected to ensure an adequately powered study.

Sampling Procedure for study participants

A total of 282 patients from the AED wards were selected by means of systematic random sampling. Using the list of patients' in each of the three emergency wards supplied antibacterial agents from the pharmacy, every third of such patient was recruited after obtaining informed consent, and followed. The selection was done to reflect the wards relative patient load. The patient load is also a reflection of the bed complement of each ward with Yellow having 18 beds, Orange 12 beds and Red 6 beds. Yellow ward had the highest number of selected patients with 131 patients, followed by Orange with 104 patients and the Red with 47 patients. The patients were recruited from 1st March, 2014 to 30th April, 2014 for the study.

Data collection on appropriate antibacterial use

The data collection form (Appendix 1) for assessing appropriate use of antibacterial agents and patients clinical outcomes was evaluated for clarity and content validity by two emergency

physician specialists before pretesting. In collecting this data, selected patients were followed daily for relevant data such as diagnosis, antibacterial agents prescribed and their dosages. In addition data obtained were dosage frequency and duration as well as the total number of antibacterial agents prescribed. Clarification with regards to use of any prescribed antibacterial agent whether as prophylactic or curative was sought from the prescribing clinician when required. Patient outcomes (i.e. clinical status) were assessed in that subset of patients on curative antibacterial therapy after 48hrs before being discharged home or transferred to the other wards outside the AED. This is because most guidelines recommend a review of antibacterial therapy 48 hours after initiating therapy (86–88). Outcomes measures used included worsening or resolution of signs and symptoms following antibacterial therapy (i.e. resolution or worsening of fever, chesty cough in respiratory infections and improvement in the general well-being of the patient). Assessment of the patients' outcomes was done clinically. Death of participants who received at least a dose of an antibacterial agent for therapeutic purposes was also noted. The data was collected by four trained pharmacists who are conversant with the antibacterial protocol in the Ghana Standard Treatment Guidelines and other standard guidelines adapted for use by the clinicians. The other guidelines included CDC recommendations (89) and the BNF(54).




Figure 2: Study flow chart on patients included in the study and monitored for antibacterial use and outcomes

c) Determining antibacterial resistance

KATH medical microbiology lab records were used.

Data Collection of bacteria resistance patterns

The data collection form (Appendix 2) for the resistance pattern was reviewed by a clinical microbiologist for clarity and content validity and pretested before use. Data on all admitted AED patients with culture and sensitivity request was extracted daily from the Medical Microbiology lab records during the study period. The patient's age, ward, sex, specimen type, diagnosis or clinical summary, the type of isolated bacteria as well as their resistance pattern to antibacterial discs in the Medical Microbiology lab were among the information obtained. The specimen type included blood, urine, cerebrospinal fluid (CSF), wound swab and others. Others were pleural fluid, ascitic fluid, knee joint aspirate and breast aspirate. Data was collected by the principal investigator.




Figure 3: Study flow chart on AED patients with biological samples assessed for resistance

3.1.6 Data Analysis

All the collected data was coded, entered into SPSS version17 data base, and analyzed. Descriptive statistics including frequency and percentage was used to determine prevalence of antibacterial use. Pattern of antibacterial use was also represented as frequencies and proportions. Total number antibacterial agents prescribed to each patient were determined. Each of the indicators of appropriate use including dose, frequency and duration was assigned a binary outcome of yes or no if correct or wrong, in relation to the patient condition and comorbidities. Descriptive analysis of resistance of bacteria isolates from collected specimen was also presented in a tabular form.

Appropriate use of an antibacterial agent was determined when the choice of selected agent, dose, and frequency was in line with the recommendations of the national standard guidelines and other international standards adapted for use at KATH. The extent of use of the commonly prescribed antibacterial agents was described by the defined daily dose/ 100 bed-days of the various agents used (Refer the formula below on how this was calculated).

Defined daily dose (DDD)/ 100 bed-days was calculated using the formula(90,91);

$$\text{DDD/100 bed-days} = \frac{\text{No. of units administered in a given period (mg)} \times 100}{\text{DDD (mg)} \times \text{no. of days in the period} \times \text{no. of beds} \times \text{occupancy index}}$$

3.1.7 Ethical Consideration

Ethical approval (CHRPE/AP/011/14) was given by the Committee on Human Research Publication and Ethics (CHRPE), KNUST. This was after the Heads of Accident and Emergency Department and Department of Clinical Microbiology, KATH were contacted for consent to carry on the study after the objectives and rationale of the study has been explained to them. Cases of suspected inappropriate antibacterial prescribing during the course of data collection were discussed with the attending physician. Non-compliance with laboratory data was handled similarly. Anonymity and confidentiality of patients data was assured throughout the study and after.

CHAPTER FOUR

4.1 RESULTS

a) Prevalence of antibacterial use

Proportion of admitted patients exposed to antibacterial agents

A total of 1119 out of the 1942 admitted patients were prescribed antibacterial agents representing a prevalence of 57.6%. For Red ward, 112 out of 174 representing 64.4% were prescribed antibacterial agents, 60.6% (n=470) for Orange ward and 54.1% (n=537) for Yellow ward.

b) Appropriateness of antibacterial use and patient outcomes

2a. Demography of study participants

A total of 282 participants were selected to be assessed for appropriateness of antibacterial use and patients outcomes. This comprised 160 (56.7%) males and 122 (43.3%) females. There were 131 participants from Yellow, 104 participants from Orange and 47 participants from Red. The mean age of the participants was 44years with a standard deviation of 21.93. Sixty-two percent (n=174) of sampled patients were prescribed antibacterial agents for curative purposes while the remainder was for prophylaxis (Table 1).

Table 1: Prophylactic and curative use of antibacterial agents in the wards

Ward	Antibacterial indication		Total (%)
	Prophylactic	Curative	
Red	9	25	34(12.1%)
Yellow	64	74	138(48.9%)
Orange	35	75	110(39%)
Total	108(38.3%)	174(61.7%)	282(100%)

The most affected body system requiring antibacterial therapy included the gastrointestinal system (n=62) followed by genito-urinary system (n=43), respiratory system (n=50) etc. (Table 2).

Table 2: Affected body systems requiring antibacterial agents

Body system affected	Antibacterial indication		Total
	Prophylactic	Curative	
Gastrointestinal	33	29	62 (22%)
Cardiovascular system	5	2	7(2.5%)
Respiratory system	3	47	50(17.7%)
Central Nervous system	13	20	33(11.7%)
Endocrine system	0	1	1(0.4%)
Musculoskeletal	25	5	30(10.6)
Skin	20	22	42 (14.9%)
Genito-urinary	7	46	53(18.8%)
Blood	2	2	4(1.4%)
Total	108(38.3)	174(61.7%)	282 (100%)

From Table 3, hypertension and HIV infection were the most frequent comorbidities in those on antibacterial therapy at the wards.

Table 3: Comorbidities of study participants

Comorbidity	Antibacterial indication		Total
	Prophylactic	Curative	
Acute respiratory distress syndrome	1	0	1
Asthma	0	4	4
Cirrhosis	1	3	4
Chronic kidney disease	0	2	2
Chronic Liver disease	0	2	2
Cerebrovascular accident	0	2	2
Diabetes mellitus	0	10	10
Diabetes mellitus/Hypertension	1	12	13
Heart failure	0	1	1
Hypertension	5	16	21
Prostate cancer	0	1	1
Peptic ulcer disease	0	2	2
HIV infection	0	16	16
Systemic Lupus Erythematosus	0	1	1
Uterine fibroid	1	0	1
Total	9	72	81

2b. Commonly prescribed antibacterial agents

As shown in Table 4, 36.5% of sampled participants in the wards were given cefuroxime, followed by metronidazole (33.7%) and ceftriaxone (32.3%). The DDD/100-bed days of cefuroxime oral and parenteral were 75.85 and 36.12 respectively.

Table 4: Pattern of prescribed antibacterials

Antibacterial agent	Antibacterial indication		Total	DDD/100 bed-days
	Prophylactic	Curative		
Ceftriaxone	22 (7.8%)	69 (24.5%)	91 (32.3%)	35.196 (P)
Cefuroxime	48 (17%)	55 (19.5%)	103 (36.5%)	36.119 (P); 75.850 (O)
Metronidazole	45 (16%)	50 (17.7%)	95 (33.7%)	27.958 (P); 20.535 (O)
Amoxicillin/Clavulanic acid	21 (7.4%)	9 (3.2%)	30 (10.6%)	6.965(P); 23.501 (O)
Ciprofloxacin	22 (7.8%)	35 (12.4%)	57 (20.2%)	28.050 (P); 31.854 (O)
Clindamycin	2 (0.7%)	17 (6%)	19 (6.7%)	2.354 (P); 10.270 (O)
Azithromycin	2 (0.7%)	29 (10.3%)	31 (11%)	0.321 (P); 44.040 (O)
Flucloxacillin	0	5 (1.8%)	5 (1.8%)	0.535 (P); 3.123 (O)
Gentamicin	0	3 (1.1%)	3 (1.1%)	0.785 (P)
Cotrimoxazole	0	13 (4.6%)	13 (4.6%)	92.298 (O)
Doxycycline	0	2 (0.7%)	2 (0.7%)	16.689 (O)
Total	108(38.3%)	174(61.7%)	282(100.0%)	

P= Parenteral O=Oral

2c. Number of antibacterial agents patient were exposed to

Of the 282 study participants, 47.9% (n=135) and 44.7% (n=126) were prescribed to 1 and 2 antibacterial agents respectively. Few patients (n=21) were on 3 or more antibacterial agents (Figure 4).




Figure 4: Number of antibacterial agents patients were exposed to.

2d. Choice of antibacterial agents used

Of the 282 participants, 72.3% (n=204) had the choice of selected antibacterial agents in line with recommendations in the standard guidelines (Figure 5).




Figure 5: Choice of selected antibacterial agent(s) in line with recommendation in approved guidelines

About 70% of the study participants (n=196) had all the parameters indicative of appropriate antibacterial therapy (i.e. Correct choice of drug, correct dosage and correct dosage frequency) (Figure 6).




Figure 6: Appropriate antibacterial therapy as indicated by the standard guidelines

2e. Physicians request for culture and sensitivity testing

Out of the 282 study participants prescribed antibacterial agents during the study period, only 46 had request for culture and sensitivity to the Medical Microbiology lab when their folders were checked during data collection. This represented 16% of study participants (Figure 7).




Figure 7: Request for culture and sensitivity testing

2g. Patient outcome following curative antibacterial therapy

One hundred and twenty-three (70.6%) of the 174 study participants were followed for outcomes assessment. The remaining 51 were lost to follow up. Fifty-six percent (n=69) of the patients showed improvement in their clinical status, 28.45% (n=35) had their condition worsening and 15.4% (n=19) died. Failure rates were higher in Red followed by Yellow ward (p=0.003).

Table 5: Patient clinical status following curative antibacterial therapy

Ward	Patient clinical status			Total
	Improvement	Worsening	Death	
Red	10	8	10	28 (22.8%)
Orange	29	18	7	54 (43.9%)
Yellow	30	9	2	41 (33.3%)
Total	69 (56.1%)	35 (28.5%)	19 (15.4%)	123 (100%)

Chi-Square Tests			
	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	15.947 ^a	4	.003
Likelihood Ratio	15.169	4	.004
Linear-by-Linear Association	3.079	1	.079
N of Valid Cases	123		

a. 1 cells (11.1%) have expected count less than 5. The minimum expected count is 4.33.

c) Resistance patterns of isolated bacteria

3a. Patient demography and type of sample taken for culture

The mean age of all patients with samples taken to the lab was 47.51 years, with a standard deviation of 22.41 and range 18 to 88 years. Ninety specimen were taken from the patients. This include specimen from 41 patients (48.2%) from Orange, 32 (37.6%) from Yellow, and 12 (14.1%) from Red. The specimen were blood samples (37), urine samples (15), cerebrospinal fluid samples (5), wound swabs (5) and 28 others, which include ascitic fluid, pleural fluid, knee joint aspirate and breast aspirate.

3b. Isolated bacteria in the specimen types

Of the 90 specimen, there was no bacterial growth in 67. On the remaining 23 with bacterial growth, 10 isolates were *E. coli* strains, 6 were Coagulase Negative *Staphylococcus* (possibly a contaminant on the skin), 4 were *Klebsiella spp*, 2 *Pseudomonas spp* and 1 MRSA (Table 6).

Table 6: Frequency of bacterial isolates from the different specimen types

Isolated organism	Specimen type					Total
	Blood	Urine	Cerebrospinal fluid	Wound swab	Others	
<i>E. coli</i>	2	5	0	2	1	10
<i>Pseudomonas spp.</i>	1	0	0	1	0	2
Coagulase Negative Staph.	5	0	0	0	1	6
MRSA	0	0	0	0	1	1
<i>Klebsiella spp.</i>	0	0	0	2	2	4
No bacterial isolate	29	10	5	0	23	67
Total	37	15	5	5	28	90

Source: Microbiology lab data (March-April, 2014)

3c. Isolated bacteria and resistance to the various antibacterial agents

Over 70% of *E. coli* strains tested against ceftriaxone, ampicillin, cefuroxime and ciprofloxacin was found to be resistant. However all tested isolates of *E. coli*, CNS, *Pseudomonas spp.* and *Klebsiella spp.* were susceptible to Amikacin (Table 7)

Table 7: Isolated organisms and their resistance to the various antibacterial agents

Resistance																	
Number of resistant isolates/ total number of that particular isolate tested (%)																	
Isolated organism	Ceftriaxone	Cefuroxime	Ceftazidime	Ampicillin	Flucloxacillin	Ciprofloxacin	Gentamicin	Erythromycin	Cotrimoxazole	Cefotaxime	Amikacin	Chloramphenicol	Vancomycin	Nutrofurantoin	Pipemidic acid	Nalidixic acid	Total
<i>E. coli</i>	3/4 (75)	7/8 (87.5)	0/1 (0)	8/8 (100)	NT	6/8 (75)	5/8 (62.5)	NT	8/8 (100)	1/2 (50)	0/8 (100)	2/2 (100)	NT	1/3 (33.3)	1/1 (100)	2/3 (66.7)	8
<i>Pseudomonas</i>	NT	NT	1/1 (100)	NT	NT	0/1 (0)	0/1 (0)	NT	NT	NT	0/2 (100)	NT	NT	NT	NT	NT	1
CNS	NT	2/6 (33.3)	NT	6/6 (100)	6/6 (100)	0/6 (0)	1/6 (16.7)	2/5 (40)	5/5 (100)	NT	0/1 (0)	NT	NT	NT	NT	NT	6
MRSA	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	0/1 (0)	NT	NT	NT	1
<i>Klebsiella</i>	3/4 (75)	4/4 (100)	0/3 (0)	4/4 (100)	NT	0/4 (0)	2/3 (66.7)	NT	4/4 (100)	0/1 (0)	0/3 (0)	2/2 (100)	NT	NT	NT	NT	4
Total	6	13	1	18	6	6	8	2	17	1	0	4	1	1	1	2	20

NT = not tested. Out of the 23 isolated organisms, 3 isolated organisms were susceptible to all the antibacterial agents tested against hence no resistance information was recorded. MRSA= Methicillin Resistant *Staphylococcus aureus* CNS= Coagulase Negative *Staphylococcus*

Source: Medical Microbiology lab data (March-April, 2014)

CHAPTER FIVE

5.1 DISCUSSION

Appropriateness of antimicrobial therapy especially in clinical settings has been a major issue advocated worldwide as a means of minimizing the ever growing threat of antimicrobial resistance. From the study, it was found that more than half of the admitted patients were exposed to antibacterial therapy. This is higher than the national average of 43 % determined from the WHO assessment of pharmaceutical situation in Ghana carried out in the year 2008 (92). This can be attributed to the higher propensity to prescribe antibacterial agents in emergency departments for suspected infections than in the general clinical care settings used in the WHO assessment. This study also demonstrated that antibacterial utilization in KATH AED was also higher compared to 14.5% in an Israel emergency department (93). Also, a study in an emergency department in the Sultanate of Oman, had a 10% antibacterial use prevalence (94) and a recent study in an Indian emergency unit had 14.89% antibacterial prevalence (95). These differences in antibacterial use in these studies might be attributable to infectious disease burdens in the locality and prescribing behaviours of the prescribers. An antibiotic prevalence study carried out in a hospital in the Netherlands found that 22.9% of patients had received antibiotic in the wards which was corroborated by their hospital pharmacy data (64). Overall the proportion of antibacterial use in patient admitted to Red, Orange and Yellow wards of AED were 64.36%, 60.57% and 54.13% respectively. Based on the South African Triage Scale (SATS), the higher rate seen in Red compared to Orange and then Yellow was expected because patients in Red are considered more ill than Orange, with Orange patients being more ill than those in Yellow.

The study showed that about a third of the antibacterials written were for prophylactic purposes whilst two thirds were for curative use. This is similar to what was found in a study in Singapore (96). However, it varied from a study in Israel where less than 10% of antibacterial use was for prophylactic purposes (97).

The most commonly prescribed antibacterial agent in the AED was cefuroxime, followed by metronidazole, ceftriaxone, ciprofloxacin, azithromycin and amoxicillin/clavulanic acid in that order. This varied from what was observed in a study conducted at the Surgical and Medical Emergency (SME) unit of Korle-bu Teaching Hospital (KBTH), Ghana which provides similar services as AED of KATH. At SME of KBTH the commonly prescribed antibacterial agent was ciprofloxacin, followed by metronidazole, amoxicillin/clavulanic acid and azithromycin in that order (98). A study in an Israeli emergency department however found cefuroxime and amoxicillin/clavulanic acid as the most prescribed antibacterial agents (99). Several factors including differences in infectious conditions burden, cost, antibacterial availability and the preferences of clinicians etc. all possibly accounted for the differences in antibacterial use.

The prescribing of one antibacterial agent in this study was 47.9% , which was lower compared to 81.3% in a Portugal emergency department (100). However more than half (52.1%) of study participants received two or more antibacterial agents. This was lower than what pertains at SME of KBTH where 62.4% received two or more antibacterial agents (98). These differences could be possibly due to differences in prescribing' practices within the different practice settings as well as the different pathologies in the conditions encountered necessitating the use of monotherapy or combination therapy.

About 30% of antibacterial therapy was considered inappropriate. This indicates that a relatively high proportion of patients needing antibacterial therapy were at risk of treatment failure because of inappropriate selection and use of antibacterial agents. This creates the conditions for the selection of resistant strains, increase the risk of toxicity from unnecessary exposure and also patient's condition could worsen with the use of wrong drug and sub-optimal doses. A study by Hang-Chen *et al* at a university hospital in Taiwan reported the effect of inappropriate antibacterial therapy on increase mortality in patients with blood streams infections (13).

Request for culture and sensitivity (C/S) testing among AED patients on antibacterial therapy was low in this study, suggesting a low use of definitive antibacterial therapy. Such approach to therapy could have implications for the development of bacterial resistant strains as a result of overexposure to antibacterial therapy which may not be needed. At the same time infections which are poorly targeted could worsen because the pathogen would not respond to the agent selected. This could result in treatment failure and high rate of deaths from infections. Some of the factors that could have led to the low use of C/S by prescribers may be the time lag in processing samples and difficulty in accessing results. C/S results are written manually and kept locally at the KATH medical microbiology lab thus is not readily accessible at the point of decision making.

Slightly more than half of the patients involved in this study responded favourably to the antibacterial therapy. However, about a third had their symptoms worsening and the rest dying. Inappropriate antibacterial therapy coupled with the issue of antibacterial resistance are all factors that could have contributed to the worsened patient symptoms and even death.

The Red ward recorded the highest numbers of deaths compared to Orange and Yellow. This was expected since the life-threatening and complicated cases are admitted to Red.

Organisms were isolated from 23 of the biological specimen sent to the Medical microbiology laboratory from the AED. Blood specimen accounted for most of the biological specimen sent for culture and sensitivity testing. Among the organisms were isolates of Coagulase Negative Staphylococcus (CNS). CNS may not be a true pathogen but a common contaminant because it is usually part of the normal skin flora and was maybe cultured because of defective skin preparation before blood specimen were taken. However, all the CNS isolates, were resistant to flucloxacillin, ampicillin, benzylpenicillin and cotrimoxazole. *E. coli* was the most commonly isolated organism in urine and is known to account for most urinary tract infections (UTIs). Isolated *E. coli* was resistant to ceftriaxone (i.e. all 3 tested isolates), ciprofloxacin, gentamicin and cotrimoxazole which are mostly used in treatment of UTIs. Resistance of *E. coli* to these antibacterial agents have been reported in other hospitals in Kumasi (101). *Klebsiella* which was the third most commonly isolated organism was resistant to cefuroxime, ampicillin, chloramphenicol and cotrimoxazole. One of the factors that might have contributed to the resistance of the above organisms is the high usage of these antibacterial agents in our clinical settings and also in community outlets. All the organisms tested against Amikacin were susceptible. Amikacin is used as second line therapy for bacterial infections in most hospitals in Ghana because it is expensive, highly nephrotoxic and not readily available in most facilities. This shows that non-excessive and prudent use of antibacterial agents can offer some protection against even drug resistant pathogens.

5.2 LIMITATIONS OF THE STUDY

Twenty percent (n=51) of patients on curative antibacterial therapy were lost to follow up in the outcomes assessment as result of being discharged or transferred outside the AED within 24 hours of admission. This made it difficult to determine the outcomes in such patients. However, the number of patients assessed represents a fair presentation of the outcome assessment.

The specimens sent to KATH Medical microbiology lab and the isolated organisms were small in number. Larger number of samples or carrying this study over a much longer period (6 months to 1 year) could have resulted in more isolates to enable a better understanding of antibacterial resistance patterns at the AED.

CHAPTER SIX

6.1 CONCLUSION

This study has shown that a high proportion of patients were exposed to antibacterial therapy at the AED of KATH. A third of antibacterial prescribing was considered inappropriate. The use of culture and sensitivity testing to guide therapy was low coupled with the presence of resistant pathogens to broad spectrum antibacterial agents like ceftriaxone and cefuroxime. The study has provided a good perspective in understanding antibacterial use practices at AED of KATH, and also a foundation to establish and/or strengthen antimicrobial stewardship programmes at the hospital.

6.2 RECOMMENDATIONS

1. Efforts should be made to ensure that antibacterial therapy should be guided by culture and sensitivity data.
2. There should be periodic reminders of all prescribers and clinical pharmacists in the hospital on resistance trends of clinically important microbes.
3. KATH management should computerize medical microbiology reports for easy access and use for health professionals involved in management of microbial infections.

REFERENCES

1. Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D, et al. Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action. *Antimicrobial Resistance and Infection Control*. 2012 Feb 14;1(1):11.
2. WHO | WHO Global Strategy Recommendations [Internet]. WHO. [cited 2013 Sep 12]. Available from: http://www.who.int/drugresistance/WHO_Global_Strategy_Recommendations/en/index.html
3. WHO | World Health Day – 7 April 2011 [Internet]. WHO. [cited 2013 Sep 12]. Available from: <http://www.who.int/world-health-day/2011/en/index.html>
4. Threat Report 2013 | Antimicrobial Resistance | CDC [Internet]. [cited 2014 Apr 4]. Available from: <http://www.cdc.gov/drugresistance/threat-report-2013/index.html>
5. Newman MJ, Frimpong E, Asamoah-Adu A, Sampane-Donkor E. Resistance to antimicrobial drugs in Ghana. Research Report of Ghana-Dutch Collaboration for Health Research and Development: Health Research Unit, Ghana Health Service; 2006.
6. Newman MJ, Frimpong E, Donkor ES, Opintan JA, Asamoah-Adu A. Resistance to antimicrobial drugs in Ghana. *Infection and drug resistance*. 2011;4:215–20.
7. Donkor ES, Nartey E. Nasal colonisation of drug resistant bacteria in Ghanaian children less than five years. *The internet Journal of Microbiology* [Internet]. 2007 [cited 2013 Sep 12];5(2). Available from: <http://ispub.com/IJMB/5/2/8871>
8. Sanaa SBBM, Adu F, Agyare C, Gbedema SY, Boamah VE, George DF. Antibiotic resistance patterns of strains of *Staphylococcus aureus* isolated from patients in three hospitals in Kumasi, Ghana. *Journal of Bacteriology Research*. 2013 Mar;5(3):35–40.
9. Roberts RR, Hota B, Ahmad I, Scott II RD, Foster SD, Abbasi F, et al. Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship. *Clinical Infectious Diseases*. 2009 Oct 15;49(8):1175–84.
10. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE. Trends in Antimicrobial Drug Development: Implications for the Future. *Clin Infect Dis*. 2004 May 1;38(9):1279–86.
11. Livermore DM, Blaser M, Carrs O, Cassell G, Fishman N, Guidos R, et al. Discovery research: the scientific challenge of finding new antibiotics. *J Antimicrob Chemother*. 2011 Sep 1;66(9):1941–4.
12. Davies J. Where have All the Antibiotics Gone? *Can J Infect Dis Med Microbiol*. 2006;17(5):287–90.

13. Chen H-C, Lin W-L, Lin C-C, Hsieh W-H, Hsieh C-H, Wu M-H, et al. Outcome of inadequate empirical antibiotic therapy in emergency department patients with community-onset bloodstream infections. *J Antimicrob Chemother.* 2013 Apr;68(4):947–53.
14. Kang C-I, Kim S-H, Park WB, Lee K-D, Kim H-B, Kim E-C, et al. Bloodstream Infections Caused by Antibiotic-Resistant Gram-Negative Bacilli: Risk Factors for Mortality and Impact of Inappropriate Initial Antimicrobial Therapy on Outcome. *Antimicrob Agents Chemother.* 2005 Feb 1;49(2):760–6.
15. Buabeng KO. Assessment of the efficacy, safety and quality of gentamicin use in Aberdeen Royal Infirmary. *Journal of Antimicrobial Chemotherapy.* 1999 Dec 1;44(6):843–5.
16. Leekha S, Terrell CL, Edson RS. General Principles of Antimicrobial Therapy. *Mayo Clin Proc.* 2011 Feb;86(2):156–67.
17. Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database of Systematic Reviews* [Internet]. John Wiley & Sons, Ltd; 1996 [cited 2013 Sep 12]. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003543.pub3/abstract>
18. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. *Critical Care.* 2011 Nov 15;15(6):R267.
19. Lindblad WJ. Considerations for determining if a natural product is an effective wound-healing agent. *Int J Low Extrem Wounds.* 2008 Jun;7(2):75–81.
20. Bassett E, Keith M, Armelagos G, Martin D, Villanueva A. Tetracycline-labeled human bone from ancient Sudanese Nubia (A.D. 350). *Science.* 1980 Sep 26;209(4464):1532–4.
21. Aminov RI. A Brief History of the Antibiotic Era: Lessons Learned and Challenges for the Future. *Frontiers in Microbiology* [Internet]. 2010 [cited 2013 Sep 12];1. Available from: <http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/?term=21687759>
22. Clardy J, Fischbach M, Currie C. The natural history of antibiotics. *Curr Biol.* 2009 Jun 9;19(11):R437–R441.
23. D’Costa VM, King CE, Kalan L, Morar M, Sung WWL, Schwarz C, et al. Antibiotic resistance is ancient. *Nature.* 2011 Sep 22;477(7365):457–61.
24. Karras D. Antibiotic misuse in the emergency department. *Acad Emerg Med.* 2006 Mar;13(3):331–3.
25. Bronzwaer SLAM. A European Study on the Relationship between Antimicrobial Use and Antimicrobial Resistance. *Emerging Infectious Diseases.* 2002 Mar;8(3):278–82.

26. Bosu WK, Ofori-Adjei D. An audit of prescribing practices in health care facilities of the Wassa West district of Ghana. *West Afr J Med*. 2000 Dec;19(4):298–303.
27. Leopold SJ, van Leth F, Tarekegn H, Schultsz C. Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a systematic review. *Journal of Antimicrobial Chemotherapy* [Internet]. 2014 May 30 [cited 2014 Jun 10]; Available from: <http://hinarilogin.research4life.org/uniquesigjac.oxfordjournals.org/uniquesig0/content/early/2014/05/30/jac.dku176.long>
28. Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA. Growing problem of multidrug-resistant enteric pathogens in Africa. *Emerging Infect Dis*. 2007 Nov;13(11):1640–6.
29. Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, et al. Antimicrobial resistance in developing countries. Part II: strategies for containment. *Lancet Infect Dis*. 2005 Sep;5(9):568–80.
30. Acquah SE, Quaye L, Sagoe K, Ziem JB, Bromberger PI, Amponsem AA. Susceptibility of bacterial etiological agents to commonly-used antimicrobial agents in children with sepsis at the Tamale Teaching Hospital. *BMC Infectious Diseases*. 2013 Feb 18;13(1):89.
31. Nys S. Antibiotic resistance of faecal *Escherichia coli* from healthy volunteers from eight developing countries. *Journal of Antimicrobial Chemotherapy*. 2004 Sep 29;54(5):952–5.
32. Namboodiri SS, Opintan JA, Lijek RS, Newman MJ, Okeke IN. Quinolone resistance in *Escherichia coli* from Accra, Ghana. *BMC Microbiology*. 2011;11(1):44.
33. Obeng-Nkrumah N, Twum-Danso K, Krogfelt KA, Newman MJ. High levels of extended-spectrum beta-lactamases in a major teaching hospital in Ghana: the need for regular monitoring and evaluation of antibiotic resistance. *Am J Trop Med Hyg*. 2013 Nov;89(5):960–4.
34. Feglo P, Adu-Sarkodie Y, Ayisi L, Jain R, Spurbeck RR, Springman AC, et al. Emergence of a Novel Extended-Spectrum-β-Lactamase (ESBL)-Producing, Fluoroquinolone-Resistant Clone of Extraintestinal Pathogenic *Escherichia coli* in Kumasi, Ghana. *Journal of Clinical Microbiology*. 2012 Dec 12;51(2):728–30.
35. Cook PP, Rizzo S, Gooch M, Jordan M, Fang X, Hudson S. Sustained reduction in antimicrobial use and decrease in methicillin-resistant *Staphylococcus aureus* and *Clostridium difficile* infections following implementation of an electronic medical record at a tertiary-care teaching hospital. *J Antimicrob Chemother*. 2011 Jan 1;66(1):205–9.
36. Adriaenssens N, Bartholomeeusen S, Ryckebosch P, Coenen S. Quality of antibiotic prescription during office hours and out-of-hours in Flemish primary care, using European quality indicators. *Eur J Gen Pract*. 2013 Sep 2;
37. Lawrence C, Tuma R, Guha S, Michael H, Lowy FD, Shuter J. Multiple antibiotic changes during the first 72 hours of hospitalization. *Am J Med Sci*. 2001 Aug;322(2):61–7.

38. Gonzales R, Camargo CA, MacKenzie T, Kersey AS, Maselli J, Levin SK, et al. Antibiotic Treatment of Acute Respiratory Infections in Acute Care Settings. *Academic Emergency Medicine*. 2006 Mar 1;13(3):288–94.
39. Stone S, Gonzales R, Maselli J, Lowenstein SR. Antibiotic prescribing for patients with colds, upper respiratory tract infections, and bronchitis: A national study of hospital-based emergency departments. *Ann Emerg Med*. 2000 Oct;36(4):320–7.
40. Thorpe JM, Smith SR, Trygstad TK. Trends in Emergency Department Antibiotic Prescribing for Acute Respiratory Tract Infections. *Ann Pharmacother*. 2004 Jun 1;38(6):928–35.
41. Xu KT, Roberts D, Sulapas I, Martinez O, Berk J, Baldwin J. Over-prescribing of antibiotics and imaging in the management of uncomplicated URIs in emergency departments. *BMC Emergency Medicine*. 2013;13(1):7.
42. Karras DJ, Ong S, Moran GJ, Nakase J, Kuehnert MJ, Jarvis WR, et al. Antibiotic use for emergency department patients with acute diarrhea: Prescribing practices, patient expectations, and patient satisfaction. *Ann Emerg Med*. 2003 Dec;42(6):835–42.
43. Stearns CR, Gonzales R, Camargo CA Jr, Maselli J, Metlay JP. Antibiotic prescriptions are associated with increased patient satisfaction with emergency department visits for acute respiratory tract infections. *Acad Emerg Med*. 2009 Oct;16(10):934–41.
44. Ong S, Nakase J, Moran GJ, Karras DJ, Kuehnert MJ, Talan DA, et al. Antibiotic use for emergency department patients with upper respiratory infections: prescribing practices, patient expectations, and patient satisfaction. *Ann Emerg Med*. 2007 Sep;50(3):213–20.
45. Gennai S, Pavese P, Vittoz J-P, Decouchon C, Remy S, Dumont O, et al. [Assessment of antibiotic prescriptions in the emergency department of a general hospital. Prospective analysis of 211 prescriptions]. *Presse Med*. 2008 Jan;37(1 Pt 1):6–13.
46. Ramos Martínez A, Cornide Santos I, Marcos García R, Calvo Corbella E. [Antibiotic prescription quality at a hospital emergency service]. *An Med Interna*. 2005 Jun;22(6):266–70.
47. Howie N, Gerstenmaier JF, Munro PT. Do peripheral blood cultures taken in the emergency department influence clinical management? *Emerg Med J*. 2007 Mar;24(3):213–4.
48. Mountain D, Bailey PM, O'Brien D, Jelinek GA. Blood cultures ordered in the adult emergency department are rarely useful: *European Journal of Emergency Medicine*. 2006 Apr;13(2):76–9.
49. Kelly AM. Clinical impact of blood cultures taken in the emergency department. *J Accid Emerg Med*. 1998 Jul;15(4):254–6.

50. Kennedy M, Bates DW, Wright SB, Ruiz R, Wolfe RE, Shapiro NI. Do Emergency Department Blood Cultures Change Practice in Patients With Pneumonia? *Annals of Emergency Medicine*. 2005 Nov 1;46(5):393–400.
51. Ramanujam P, Rathlev NK. Blood Cultures Do Not Change Management in Hospitalized Patients with Community-acquired Pneumonia. *Academic Emergency Medicine*. 2006 Jul 1;13(7):740–5.
52. Abe T, Ishimatsu S, Tokuda Y, Birrer RB. Usefulness of initial blood cultures in patients admitted with pneumonia from an emergency department in Japan. *Journal of Infection and Chemotherapy*. 2009;15(3):180–6.
53. Shapiro NI, Wolfe RE, Wright SB, Moore R, Bates DW. Who Needs a Blood Culture? A Prospectively Derived and Validated Prediction Rule. *The Journal of Emergency Medicine*. 2008 Oct;35(3):255–64.
54. British Medical Association, Royal Pharmaceutical Society of Great Britain. BNF 67: British national formulary : March 2014 - September 2014. 2014.
55. Besser RE. Antimicrobial prescribing in the United States: good news, bad news. *Ann Intern Med*. 2003 Apr 1;138(7):605–6.
56. Kunin CM, Tupasi T, Craig WA. Use of Antibiotics. A Brief Exposition of the Problem and Some Tentative Solutions. *Ann Intern Med*. 1973 Oct 1;79(4):555–60.
57. Gyssens IC, van den Broek PJ, Kullberg B, Hekster YA, Van Der Meer JWM. Optimizing antimicrobial therapy. A method of antimicrobial drug use evaluation. *J Antimicrob Chemother*. 1992;30:724–7.
58. Van Der Meer J w. m., Gyssens I c. Quality of antimicrobial drug prescription in hospital. *Clinical Microbiology and Infection*. 2001;7:12–5.
59. Pulcini C, Cua E, Lieutier F, Landraud L, Dellamonica P, Roger PM. Antibiotic misuse: a prospective clinical audit in a French university hospital. *Eur J Clin Microbiol Infect Dis*. 2007 Apr;26(4):277–80.
60. Raji MA, Jamal W, Ojemhen O, Rotimi VO. Point-surveillance of antibiotic resistance in Enterobacteriaceae isolates from patients in a Lagos Teaching Hospital, Nigeria. *Journal of Infection and Public Health* [Internet]. 2013 Jun [cited 2013 Sep 10]; Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1876034113000762>
61. Ingram PR, Seet JM, Budgeon CA, Murray R. Point-prevalence study of inappropriate antibiotic use at a tertiary Australian hospital. *Intern Med J*. 2012 Jun;42(6):719–21.
62. Pakyz AL, Dwyer LL. Prevalence of Antimicrobial Use among United States Nursing Home Residents: Results from a National Survey. *Infection Control and Hospital Epidemiology*. 2010 Jun;31(6):661–2.

63. Willemsen I, van der Kooij T, van Benthem B, Wille J, Kluytmans J. Appropriateness of antimicrobial therapy: a multicentre prevalence survey in the Netherlands, 2008-2009. *Euro Surveill*. 2010 Nov 18;15(46).
64. Willemsen I, Groenhuijzen A, Bogaers D, Stuurman A, van Keulen P, Kluytmans J. Appropriateness of antimicrobial therapy measured by repeated prevalence surveys. *Antimicrob Agents Chemother*. 2007 Mar;51(3):864–7.
65. WHO | Drug Utilization: ATC/DDD [Internet]. WHO. [cited 2013 Sep 12]. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/utilization/en/index.html
66. Sözen H, Gönen I, Sözen A, Kutlucan A, Kalemci S, Sahan M. Application of ATC/DDD methodology to evaluate of antibiotic use in a general hospital in Turkey. *Annals of Clinical Microbiology and Antimicrobials*. 2013 Sep 3;12(1):23.
67. Antibiotic Resistance [Internet]. [cited 2014 Jun 5]. Available from: <http://ghndp.org/reactcs0/index.php/16-newsflash/react-cso-project-rational-use-2/23-resistance-to-antimicrobial-drugs-in-ghana-2>
68. Giedraitienė A, Vitkauskienė A, Naginienė R, Pavilonis A. Antibiotic resistance mechanisms of clinically important bacteria. *Medicina (Kaunas)*. 2011;47(3):137–46.
69. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. *American Journal of Infection Control*. 2006 Jun;34(5):S3–S10.
70. Shears P. Antibiotic resistance in the tropics. *Epidemiology and surveillance of antimicrobial resistance in the tropics*. *Trans R Soc Trop Med Hyg*. 2001 Apr;95(2):127–30.
71. Antimicrobial Resistance: A Primer : Factors in Antimicrobial Resistance [Internet]. [cited 2014 Jul 2]. Available from: http://www.medscape.com/viewarticle/729196_4
72. Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. *Emerging Infect Dis*. 1999 Feb;5(1):18–27.
73. Levy SB. Factors impacting on the problem of antibiotic resistance. *Journal of Antimicrobial Chemotherapy*. 2002 Jan 1;49(1):25–30.
74. Ashiru-Oredope D, Sharland M, Charani E, McNulty C, Cooke J. Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: Start Smart—Then Focus. *J Antimicrob Chemother*. 2012 Jul 1;67(suppl 1):i51–i63.
75. DiazGranados CA. Prospective audit for antimicrobial stewardship in intensive care: Impact on resistance and clinical outcomes. *American Journal of Infection Control*. 2012 Aug;40(6):526–9.

76. Nathwani D, Sneddon J, Malcolm W, Wiuff C, Patton A, Hurding S, et al. Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme. *Int J Antimicrob Agents*. 2011 Jul;38(1):16–26.
77. Impact of Antimicrobial Stewardship Program on Antimicrobial Resistance | Evidence | Get Smart for Healthcare | CDC [Internet]. [cited 2014 Jun 5]. Available from: <http://www.cdc.gov/getsmart/healthcare/evidence/asp-int-am-resistance.html>
78. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: a systematic review. *J Antimicrob Chemother*. 2011 Jun;66(6):1223–30.
79. MacDougall C, Polk RE. Antimicrobial Stewardship Programs in Health Care Systems. *Clin Microbiol Rev*. 2005 Oct 1;18(4):638–56.
80. Boyles TH, Whitelaw A, Bamford C, Moodley M, Bonorchis K, Morris V, et al. Antibiotic Stewardship Ward Rounds and a Dedicated Prescription Chart Reduce Antibiotic Consumption and Pharmacy Costs without Affecting Inpatient Mortality or Re-Admission Rates. *PLoS ONE*. 2013 Dec 9;8(12):e79747.
81. Tunger O, Karakaya Y, Cetin CB, Dinc G, Borand H. Rational antibiotic use. *J Infect Dev Ctries*. 2009;3(2):88–93.
82. The South African Triage Scale (SATS) : EMSSA [Internet]. [cited 2014 Jun 25]. Available from: <http://emssa.org.za/sats/#>
83. Rominski S. The validity of the South African Triage Scale at a tertiary care centre, Kumasi, Ghana. *African Journal of Emergency Medicine*. 2013 Dec;3(4):S8–S9.
84. Gottschalk SB, Wood D, DeVries S, Wallis LA, Bruijns S, Cape Triage Group. The Cape Triage Score: a new triage system South Africa. Proposal from the Cape Triage Group. *Emerg Med J*. 2006 Feb;23(2):149–53.
85. Emergency Medicine Society of South Africa : EMSSA Practice Guideline EM014: implementation of the South African Triage Scale. [Internet]. [cited 2014 Jun 25]. Available from: <http://emssa.org.za/documents/em014.pdf>
86. Antibiotic Awareness Week - Fact Sheet - Fact-Sheet-Action-4_Review-and-reassess-antibiotics-at-48-hours.pdf [Internet]. [cited 2014 Jun 29]. Available from: http://www.safetyandquality.gov.au/wp-content/uploads/2013/11/Fact-Sheet-Action-4_Review-and-reassess-antibiotics-at-48-hours.pdf
87. Anti-Microbial stewardship - dh_131181.pdf [Internet]. [cited 2014 Jun 29]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215308/dh_131181.pdf

88. CDC - Blogs - Safe Healthcare – Let's Take an Antibiotic Time Out [Internet]. [cited 2014 Jun 29]. Available from: <http://blogs.cdc.gov/safehealthcare/2010/11/16/let%e2%80%99s-take-an-antibiotic-time-out/>
89. CDC - Diseases and Conditions [Internet]. [cited 2012 Sep 10]. Available from: <http://www.cdc.gov/DiseasesConditions/>
90. Monnet DL. ABC-Calc. Antibiotic consumption calculator. [Microsoft@Excel application]. Version 3.1. Copenhagen (Denmark). Statens Serum Institut; 2006.
91. ESCMID: ABC Calc [Internet]. [cited 2014 May 7]. Available from: https://www.escmid.org/research_projects/study_groups/esgap/abc_calc/
92. Arhinful DK. WHO PHARMACEUTICAL SITUATION ASSESSMENT–LEVEL II–. Health Facilities Survey in Ghana MOH Ghana, Accra [Internet]. 2009; Available from: http://www.moh-ghana.org/UploadFiles/Publications/Ghana_baseline_WHO_level_II_Health_Facility_Survey140204075637.pdf
93. Ojeniran M, Shouval R, Miskin IN, Moses AE, Shmueli A. Costs of appropriate and inappropriate use of antibiotics in the emergency department. *Isr Med Assoc J*. 2010 Dec;12(12):742–6.
94. Al Balushi K, Al-Shibli S, Al-Zakwani I. Drug utilization patterns in the emergency department: A retrospective study. *Journal of Basic and Clinical Pharmacy*. 2014;5(1):1.
95. Kaur S, Rajagopalan S, Kaur N, Shafiq N, Bhalla A, Pandhi P, et al. Drug Utilization Study in Medical Emergency Unit of a Tertiary Care Hospital in North India. *Emergency Medicine International*. 2014;2014:1–5.
96. Lim VK, Cheong YM, Suleiman AB. Pattern of antibiotic usage in hospitals in Malaysia. *Singapore Med J*. 1993 Dec;34(6):525–8.
97. Raveh D, Levy Y, Schlesinger Y, Greenberg A, Rudensky B, Yinnon AM. Longitudinal surveillance of antibiotic use in the hospital. *QJM*. 2001 Mar;94(3):141–52.
98. Acheampong F. Pattern of Antibacterial Use: A Case Study of the Surgical And Medical Emergency Unit of Korle Bu Teaching Hospital, Accra, Ghana [Internet]. KNUST; Available from: <http://dspace.knust.edu.gh:8080/jspui/bitstream/123456789/867/1/FRANKLIN%20ACHEAMPONG.pdf>
99. Raz R, Hassin D, Kitzes-Cohen R, Rottensterich E. Antibiotic prescribing for adults and children in Israeli emergency rooms. *Int J Antimicrob Agents*. 2003 Aug;22(2):100–5.
100. Vieira AL, Capela C. Appropriateness of antibiotic prescriptions for hospital emergency department patients. *European Journal of Internal Medicine*. 2013 Oct 1;24:e198–e199.

101. George DF, Gbedema SY, Agyare C, Adu F, Boamah VE, Tawiah AA, et al. Antibiotic Resistance Patterns of *Escherichia coli* Isolates from Hospitals in Kumasi, Ghana. *ISRN Microbiol.* 2012;2012:658470.

APPENDICES

APPENDIX 1: DATA COLLECTION FORM FOR WARD DATA (Tick where appropriate)

Study ID.....[] [] []

SECTION A: PATIENTS DETAILS

1. Age[] []years
2. Gender.....¹[]Male ²[]Female
3. Ward.....¹[]Red ²[]Yellow ³[]Orange

SECTION B: ANTIBACTERIAL USE

4. Current medical diagnosis/
Comorbidities
.....
.....
.....

5. Indication for use of antibacterial agent(s).....¹[] Prophylactic ²[] Therapeutic
6. Antibacterial information (Name, dose, frequency, duration & route of administration)

Date	Name, dose frequency, duration and route of administration	Comments/ reasons for any change of antibacterial agent

7. Number of antibacterial agents prescribed for patient.....[] []

8. Are the antibacterial agents used for the condition in line with what is recommended in the STG and other guidelines? ¹[] Yes ²[] No

9. Is there any request for culture and sensitivity testing? ¹[] Yes ²[] No

10. Is there an improvement the condition of patient after 48hrs?

¹[] resolution of symptoms (including fever, cough, etc. or general well-being of the patient)

²[] worsening symptoms

³[] Death after exposure to antibacterial therapy

APPENDIX 2: DATA COLLECTION FORM FOR MICROBIOLOGY LAB

Study ID..... [] [] []

1. Age[] [] years

2. Gender..... ¹[] Male ²[] Female

3. Ward.....¹[] Red ²[] Yellow ³[] Orange

4. Specimen type

¹[] Blood ²[] Urine ³[] Sputum ⁴[] Cerebrospinal fluid ⁵[] wound swab

⁶[] Others. Specify.....

5. Clinical summary

.....
.....
.....

6. Bacteria Isolate (s).....

7. Susceptibility (key: 's' = sensitive and 'r' = resistant nt= not tested)

¹[] Ceftriaxone ²[] Cefuroxime ³[] Ceftazidime ⁴[] Ampicillin ⁵[] Flucloxacillin

⁶[] Amoxicillin/Clavulanic ⁷[] Benzylpenicillin ⁸[] Ciprofloxacin

⁹[] Gentamicin ¹⁰[] Erythromycin ¹¹[] Doxycycline ¹²[] Azithromycin

¹³[] Metronidazole ¹⁴[] Cotrimoxazole ¹⁵[] Amikacin ¹⁶[] Cefotaxime

¹⁷[] Chloramphenicol ¹⁸[] Vancomycin ¹⁹[] Cefoxitin ²⁰[] Nitrofurantoin

²¹[] Pipemidic acid ²²[] Nalidixic acid ²³[] Others. Specify.....

APPENDIX 3: COPY OF ETHICAL APPROVAL LETTER



KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
COLLEGE OF HEALTH SCIENCES

SCHOOL OF MEDICAL SCIENCES / KOMFO ANOKYE TEACHING HOSPITAL
COMMITTEE ON HUMAN RESEARCH PUBLICATION AND ETHICS



Our Ref: CHRPE/AP/011/14

29th January, 2014.

Mr. Daniel Appiah
Pharmacy Department-
Accident and Emergency
Komfo Anokye Teaching Hospital
Post Office Box 1934
KUMASI.

Dear Sir,

LETTER OF APPROVAL

Protocol Title: *"Antibiotic Use and Resistance at the Accident and Emergency Department, KATH."*

Proposed Site: *Accident and Emergency Department, KATH and Department of Clinical Microbiology, KATH.*

Sponsor: *Principal Investigator.*

Your submission to the Committee on Human Research, Publications and Ethics on the above named protocol refers.

The Committee reviewed the following documents:

- A notification letter of 24th December, 2013 from the Komfo Anokye Teaching Hospital (study site) indicating approval for the conduct of the study in the Hospital.
- A Completed CHRPE Application Form.
- Research Proposal.
- Data Collection Form.


The Committee has considered the ethical merit of your submission and approved the protocol. The approval is for a fixed period of one year, renewable annually thereafter. The Committee may however, suspend or withdraw ethical approval at anytime if your study is found to contravene the approved protocol.

Data gathered for the study should be used for the approved purposes only. Permission should be sought from the Committee if any amendment to the protocol or use, other than submitted, is made of your research data.

The Committee should be notified of the actual start date of the project and would expect a report on your study, annually or at close of the project, whichever one comes first. It should also be informed of any publication arising from the study.

Thank you Sir, for your application.

Yours faithfully,


Rev. Prof. John Appiah-Poku
Honorary Secretary
FOR: CHAIRMAN